Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
100
datasets available to search
ShareScore release 0.9.0
Dataset results
100 results for “Yellow fever”
Human Immune Responses to Yellow Fever Vaccination
ClinicalTrials.gov study NCT00694655. IPD Sharing: NO. Countries: 1. Publications: 1.
Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old
ClinicalTrials.gov study NCT03725618. IPD Sharing: NO. Countries: 1. Publications: 2.
Data from: Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype
Open the record for dataset details and reuse information.
Data from: A single 17D Yellow Fever vaccination provides lifelong immunity; characterization of Yellow-Fever-specific neutralizing antibody and T-cell responses after vaccination
Introduction: Prompted by recent amendments of Yellow Fever (YF) vaccination guidelines from boost to single vaccination strategy and the paucity of clinical data to support this adjustment, we used the profile of the YF-specific CD8+ T-cell subset profiles after primary vaccination and neutralizing antibodies as a proxy for potentially longer lasting immunity. Methods and Findings: PBMCs and serum were collected in six individuals on days 0, 3, 5, 12, 28 and 180, and in 99 individuals >10 years after YF-vaccination. Phenotypic characteristics of YF- tetramer+ CD8+ T-cells were determined using class I tetramers. Antibody responses were measured using a standardized plaque reduction neutralization test (PRNT). Also, characteristics of YF-tetramer positive CD8+ T-cells were compared between individuals who had received a primary- and a booster vaccination. YF-tetramer+ CD8+ T-cells were detectable on day 12 (median tetramer+ cells as percentage of CD8+ T-cells 0.2%, range 0.07–3.1%). On day 180, these cells were still present (median 0.06%, range 0.02–0.78%). The phenotype of YF-tetramer positive CD8+ T-cells shifted from acute phase effector cells on day 12, to late differentiated or effector memory phenotype (CD45RA-/+CD27-) on day 28. Two subsets of YF-tetramer positive T-cells (CD45RA+CD27- and CD45RA+CD27+) persisted until day 180. Within all phenotypic subsets, the T-bet: Eomes ratio tended to be high on day 28 after vaccination and shifted towards predominant Eomes expression on day 180 (median 6.0 (day 28) vs. 2.2 (day 180) p = 0.0625), suggestive of imprinting compatible with long-lived memory properties. YF-tetramer positive CD8+ T-cells were detectable up to 18 years post vaccination, YF-specific antibodies were detectable up to 40 years after single vaccination. Booster vaccination did not increase titers of YF-specific antibodies (mean 12.5 vs. 13.1, p = 0.583), nor induce frequencies or alter phenotypes of YF-tetramer+ CD8+ T-cells. Conclusion: The presence of a functionally competent YF-specific memory T-cell pool 18 years and sufficient titers of neutralizing antibodies 35–40 years after first vaccination suggest that single vaccination may be sufficient to provide long-term immunity.
Yellow fever outbreak temporarily changes dispersal patterns in an endangered primate
Open the record for dataset details and reuse information.
Figure 5 in Indiscriminate ingestion of entomopathogenic nematodes and their symbiotic bacteria by Aedes aegypti larvae: a novel strategy to control the vector of Chikungunya, dengue and yellow fever
Figure 5. Aedes aegypti larval mortality when exposed to 1000 infective juveniles (IJs) of Heterorhabditis bacteriophora in different volumes of water.
Figure1 in Indiscriminate ingestion of entomopathogenic nematodes and their symbiotic bacteria by Aedes aegypti larvae: a novel strategy to control the vector of Chikungunya, dengue and yellow fever
Figure1. Susceptibility of Aedes aegypti larvae to different species of EPNs. Five 3rd instar larvae exposed to 500 infective juveniles (IJs) and mortality assessed daily at 1-day, 2- and 3-days post-inoculation (DPI).
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
ClinicalTrials.gov study NCT05421611. IPD Sharing: YES. Countries: 1. Publications: 0.
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by
ClinicalTrials.gov study NCT02699099. IPD Sharing: YES. Countries: 1. Publications: 0.
Trial of an Inactivated Yellow Fever Virus Vaccine
ClinicalTrials.gov study NCT05172544. IPD Sharing: NO. Countries: 1. Publications: 0.
The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
ClinicalTrials.gov study NCT04269265. IPD Sharing: NO. Countries: 2. Publications: 0.
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
ClinicalTrials.gov study NCT05447377. IPD Sharing: YES. Countries: 2. Publications: 0.
Booster Vaccine for Yellow Fever
ClinicalTrials.gov study NCT05332197. IPD Sharing: UNDECIDED. Countries: 0. Publications: 14.
Data from: A single 17D Yellow Fever vaccination provides lifelong immunity; characterization of Yellow-Fever-specific neutralizing antibody and T-cell responses after vaccination
Open the record for dataset details and reuse information.
The molecular basis for the attenuation of the yellow fever 17D vaccine [wtYFV_RNAseq]
GEO Series GSE275507. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing.
Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination
GEO Series GSE253538. Macaca fascicularis. 81 samples. Type: Expression profiling by high throughput sequencing.
The molecular basis for the attenuation of the yellow fever 17D vaccine [chimerasYFVs_RNAseq]
GEO Series GSE275508. Homo sapiens. 35 samples. Type: Expression profiling by high throughput sequencing.
ATAC-seq analysis of human CD8 T cells specific for the NS4B-214 epitope in the Yellow fever vaccine YFV-17D strain
GEO Series GSE101609. Homo sapiens. 31 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Evaluation of safety and immuno-efficacy of a next generation live attenuated yellow fever vaccine in cynomolgus macaques
GEO Series GSE222229. Macaca fascicularis. 164 samples. Type: Expression profiling by high throughput sequencing.
Single Cell RNA-seq of the draining lymph nodes of mice treated with either 3M052 or Yellow Fever Vaccine (YF)
GEO Series GSE180384. Mus musculus. 120 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.